Innovative Technologies for Molecular Analysis of Cancer (Sbir/Sttr)

The summary for the Innovative Technologies for Molecular Analysis of Cancer (Sbir/Sttr) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Innovative Technologies for Molecular Analysis of Cancer (Sbir/Sttr): This RFA will utilize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) mechanisms, but will be run in parallel with a RFA of identical scientific scope (CA-05-002, that will utilize the exploratory/developmental research Phase I (R21) mechanism and the exploratory/developmental research Phase II (R33) mechanism . The National Cancer Institute (NCI) invites applications for research projects proposing the development of highly innovative cancer-relevant technologies. Technology encompasses methods and tools that enable research, including, but not limited to, instrumentation, techniques, and devices. Technology is distinct from resources such as databases, reagents, and tissue repositories. Applications for support of such resources will not be considered to be responsive to this RFA. Technologies solicited include, but are not necessarily limited to, those that are suitable for the detection of alterations and instabilities of genomic DNA; measurement of the expression of genes and gene products, including proteins; analysis and detection of gene and/or cellular products, including post-translational modifications and functions of proteins; identification and characterization of exogenous infectious agents in cancer; and assaying the functions of major signal transduction networks involved in cancer. Developing technologies would include those that will support molecular analysis in vitro, in situ, or in vivo in discovery processes as well as in pre-clinical models and clinical research. This initiative is part of a broader technology development program within the NCI to harness technology in the fight against cancer. The NCI technology program underscores the desire of NCI to develop and integrate novel and emerging technologies in the support of cancer research, diagnosis, and treatment. In the research continuum of discovery, development, and delivery, this program accelerates development and delivery. This specific initiative will serve as the discovery tool of the larger program by soliciting and funding highly innovative, high risk and cancer-relevant technology development projects associated with the molecular analysis of cancer. This initiative capitalizes on both the success and intent of the original NCI sponsored Innovative Molecular Analysis Technologies (IMAT) program in bringing together a multi-disciplinary group of scientists and engineers to work on cancer and the expansion of interest in technology development across the NCI and other NIH institutes. This continuation of the IMAT program consists of the following three initiatives: Innovative Technologies for the Molecular Analysis of Cancer; Innovations in Cancer Sample Preparation; and Application of Emerging Technologies for Cancer Research. This RFA is designed to support technology development projects. Technologies developed or adapted for sample preparation methodology may be most suitable for RFA (CA-05-008), Innovations in Cancer Sample Preparation SBIR/STTR ( ). Research projects to evaluate emerging technologies that are ready for initial clinical or biological application in cancer research may be most suitable for RFA (CA-05-007), Application of Emerging Technologies for Cancer Research SBIR/STTR ( 007.html ) (see MECHANISMS OF SUPPORT). Researchers who emphasize the assessment of in vivo imaging technologies as the primary focus of their grant applications should contact the Cancer Imaging Program for information on appropriate funding opportunities. Researchers focusing on applying new bioinformatics or statistical techniques as the primary focus of their applications should consider one of the BISTI initiatives (
Federal Grant Title: Innovative Technologies for Molecular Analysis of Cancer (Sbir/Sttr)
Federal Agency Name: National Institutes of Health
Grant Categories: Health Education
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-05-006
Type of Funding: Grant
CFDA Numbers: 93.39393.394
CFDA Descriptions: Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research
Current Application Deadline: No deadline provided
Original Application Deadline: March 10, 2004; June 17, 2004; October 18, 2004
Posted Date: Aug 25, 2004
Creation Date: Aug 25, 2004
Archive Date: Nov 17, 2004
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: 93.395 -- Cancer Treatment Research
Applicants Eligible for this Grant
State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
Webmaster, NIH, Webmaster, Phone not available, Fax not available, Email Webmaster, NIH
More Grants from the National Institutes of Health
Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan... is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2019